Search
Streptococcus pneumoniae type 7f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10325ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTORStreptococcus pneumoniae type 9v capsular polysaccharide antigen
go.drugbank.com/drugs/DB10328ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTORStreptococcus pneumoniae type 19f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10336ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTORSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high
Streptococcus pneumoniae type 3 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10321ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADETDanaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnWhile it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan.
Flortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalIt was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114] … [A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease.
Categories: Compounds used in a research, industrial, or household settingTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Although previous NK3 receptor antagonists exist, such as osanetant and talnetant, only fezolinetant showed tangible effects on the HPC axis, potentially due to its favorable pharmacokinetics … Women undergoing abrupt menopause due to oophorectomy also experienced more severe symptoms than those going through a gradual transition.